Cancer drugs and the heart: importance and management.
暂无分享,去创建一个
[1] H. Boezen,et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Jong-Hyeon Jeong,et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Feldman,et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Choueiri,et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] I. Flinn,et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. , 2011, The Lancet. Oncology.
[6] D. V. Von Hoff,et al. A historical perspective of anthracycline cardiotoxicity. , 2011, Heart failure clinics.
[7] M. Gail,et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Munir Pirmohamed,et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.
[9] C. Marosi,et al. Prediction of venous thromboembolism in cancer patients. , 2010, Blood.
[10] R. Kao,et al. Overexpression of Vascular Endothelial Growth Factor 165 (VEGF165) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis , 2010, Journal of chemotherapy.
[11] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[12] Michael S. Ewer,et al. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know , 2010, Nature Reviews Cardiology.
[13] R. Coombes,et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] V. Cornelius,et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.
[15] M. Maitland,et al. Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.
[16] T. Choueiri,et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Shenhong Wu,et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. , 2010, American journal of hypertension.
[18] N. Pavlakis,et al. Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina , 2010, Internal medicine journal.
[19] J. Ferlay,et al. Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.
[20] David O. Martin,et al. Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. , 2010, The American journal of cardiology.
[21] D. Pfister,et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] F. Veglia,et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.
[23] H. Caron,et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.
[24] R. Autorino,et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Helen X. Chen,et al. Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.
[26] E. Yeh,et al. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.
[27] M. Piccart-Gebhart,et al. Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? , 2009, Targeted Oncology.
[28] F. Goldwasser,et al. Hypertension as a surrogate marker for the activity of anti-VEGF agents. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] K. Stergiopoulos,et al. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.
[30] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[31] Narine Sarvazyan,et al. Anthracycline cardiotoxicity: from bench to bedside. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Glick,et al. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] E. Perez,et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. , 2008, Mayo Clinic proceedings.
[34] A. Kudelka,et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. , 2008, The Lancet. Oncology.
[35] H. Dickinson,et al. Cardioprotective interventions for cancer patients receiving anthracyclines. , 2008, The Cochrane database of systematic reviews.
[36] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[37] Gary H Lyman,et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] R. Munden,et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] G. D. De Keulenaer,et al. Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure , 2007, Circulation.
[40] F. Kabbinavar,et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.
[41] A. Liem,et al. [Myocardial ischaemia as a result of treatment with capecitabine]. , 2007, Nederlands tijdschrift voor geneeskunde.
[42] R. A. Etten,et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.
[43] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] H. Kantarjian,et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.
[45] H. V. D. van der Vliet,et al. [Myocardial ischaemia as a result of treatment with capecitabine]. , 2007, Nederlands tijdschrift voor geneeskunde.
[46] Brian Walters,et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.
[47] J. Elaerts,et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[48] H. Caron,et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. , 2006, The Cochrane database of systematic reviews.
[49] V. Valero,et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Douglas L Mann,et al. Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.
[51] B. Hesse,et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction , 2004, European journal of heart failure.
[52] G. Martinelli,et al. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.
[53] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[54] A. Santoro,et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[56] B. Zaret,et al. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era , 2003, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[57] B. Jensen,et al. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[58] G. Martinelli,et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] D. Sawyer,et al. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.
[60] J. Hartikainen,et al. Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction , 2002, Journal of internal medicine.
[61] S. Soignet,et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] J. Schulz-Menger,et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. , 2001, American heart journal.
[63] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[64] R. Nagai,et al. Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.
[65] S. Lipsitz,et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.
[66] C. Carrasco,et al. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. , 1994, Ultrastructural pathology.
[67] S. Liu,et al. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.
[68] E. Cook,et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] D. Urbanová. The role of endomyocardial biopsy in the diagnosis and treatment of heart disease. , 1989, Acta Universitatis Carolinae. Medica.
[70] S. Saletan. Mitoxantrone: an active, new antitumor agent with an improved therapeutic index. , 1987, Cancer treatment reviews.
[71] L. Mancuso. Prinzmetal's angina during 5-fluorouracil chemotherapy. , 1987, The American journal of medicine.
[72] S. Wallace,et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.